Pre-made gene ORF plasmids for 2019 nCoV (SARS2 coronavirus, COVID-19)

COVID-19, a novel pathogenic coronavirus (2019-nCoV or SARS-CoV2) induced disease, emerged in China and spread globally rapidly.

GeneMedi offers pre-made gene ORF plasmids for 2019 nCoV (SARS2 coronavirus, COVID-19) as shown below: N protein(Nucleocapsid), S protein(Spike, full lenth), S1 protein(Spike), S protein RBDS protein (Spike receptor binding domain), Spike mutation (mutation of D614G, S943P, V367F, G476S, V483A, H49Y, Q239K, A831V, P1263L, D839Y/N/E, D839Y, D839N, D839E, P2-mutated Spike protein trimer variant ( P2-mutant, S1/S2 cleavage site（furin cleavage sequence)-mutant, trimerization modified), Spike(S1+S2) – B.1.1.7 lineage, Spike(S1+S2)-N501Y mutation, Spike (S1+S2)-HV 69-70 Deletion mutation(ΔH69/ΔV70) ), E protein(Envelope), M protein, ORF1ab/3a/6/7/8/10.

The pre-made gene ORF vector of 2019 nCoV (SARS2 coronavirus) can be used for mammalian expression or E.coli expression dependent on the CMV promoter or T7 protomer.

GeneMedi also provides pre-made the lentivirus, adenovirus and AAV vector for the gene ORF plasmids of 2019 nCoV (SARS2 coronavirus).

GeneMedi has submitted a preprints review about COVID-19 and 2019-nCoV.

Click here for the full-text reading:
Viral vector-based vaccine; DNA-based vaccine; RNA based vaccine – A landscape for vaccine technology against infectious disease, COVID-19 and tumor.

An Insight of comparison between COVID-19 (2019-nCoV disease) and SARS in pathology and pathogenesis

Landscape Coronavirus Disease 2019 test (COVID-19 test) in vitro — A comparison of PCR vs Immunoassay vs Crispr-Based test

In the mission of helping global scientists for the development of diagnosis and drug against 2019 nCoV(SARS2 coronavirus), GeneMedi scientists will keep moving.